Member Login
|
Site Map
|
Disclaimer
|
Contact
|
Bookmark
Advanced Search
Text Size
|
Friday, September 10, 2010
Home
Home
>
Neura
>
Pharmacogenomic Analysis in Multiple Sclerosis
>
Hot Topic: Pharmacogenomic Analysis in Multiple Sclerosis
>
References
References
1. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.
Lancet
. 1998;352:1498-1504. [
PubMed
]
2. Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response.
Mult Scler
. 2002;8:2-9. [
PubMed
]
3. O’Doherty C, Villoslada P, Vandenbroeck K. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes.
Cytokine Growth Factor Rev
. 2007;18:211-222. [
PubMed
]
4. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic.
Nat Rev Genet
. 2003;4:937-947. [
PubMed
]
5. van Baarsen LGM, Vosslamber S, Tijssen M, ogenomics of therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
PLoS ONE
. 2008;3:e1927(1-9). [
PubMed
]
6. Singh MK, Scott TF, LaFramboise WA, et al. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing b-interferon therapy.
J Neurol Sci
. 2007;258:52-59. [
PubMed
]
7. Goertsches R, Zettl UK. MS therapy research applying genome-wide RNA profiling of peripheral blood.
Int MS J
. 2007;14:98-107. [
PubMed
]
8. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
Arch Neurol
. 2008;65;337-344. [
PubMed
]
9. Fernald GH, Knott S, Pachner A, et al. Genome-wide network analysis reveals the global properties of IFN-b immediate transcriptional effects in humans.
J Immunol
. 2007;178:5076-5085. [
PubMed
]
10. Grossman I, Avidan N, Singer C, et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.
Pharmacogenet Genomics
. 2007;17;657-666. [
PubMed
]
11. Garren H, Robinson WH, Krasulova E, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
Ann Neurol
. 2008;63:611-620. [
PubMed
]
12. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Arch Neurol
. 2007;64:1407-1415. [
PubMed
]
13. Auman JT, McLeod HL. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity.
Drug Metab Rev
. 2008;40:303-315. [
PubMed
]
14. Van Schaik RHN. CYP450 pharmacogenetics for personalizing cancer therapy.
Drug Resist Updat
. 2008;11:77-98. [
PubMed
]
15. Brugts JJ, Jan Danser AH, de Maat MPM, et al. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps toward tailored drug therapy.
Curr Opin Cardiol
. 2008;23:296-301. [
PubMed
]
16. Lee C, Morton CC. Structural genomic variation and personalized medicine.
N Engl J Med
. 2008;358:740-741. [
PubMed
]
Neura.net is administered, managed, and populated by Expert Medical Education, a company dedicated to the education of healthcare professionals. The individual educational materials available here are supported by educational grants from Teva Neuroscience. This site is intended for U.S. audiences only. This Web site is for use by healthcare professionals only. It is not meant to serve as a substitute for a consultation with your physician. If you are a patient and would like to see Neura.net's educational material for patients,
click here
. Some discussions of drugs and devices contained on this Web site may include mention of uses that have not been evaluated by the United States Food and Drug Administration for safety and efficacy. Please consult complete prescribing information for any of the drugs and devices discussed before using them.
© 2010 Neura.net. All rights reserved.
